− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today's Patients – – Only Therapeutic Approved in the U.S. to Address Both Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis − – Alnylam Offers Multiple Programs to Support Broad and Seamless Patient Access; Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for AMVUTTRA – – Alnylam to Host Conference Call Today at 6:00 pm ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today anno

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent d

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, Cardiovascular Disease, and Neuroscience, each representing a blockbuster opportunity – – Announces TRITON Phase 3 program for next-generation TTR silencer nucresiran in ATTR-CM and hATTR-PN, targeting durable franchise leadership – – Provides details about Phase 3 cardiovascular outcomes trial for zilebesiran, poised to transform the treatment of hypertension in patients with high CV risk – – Highlights new clinical programs, including for Huntington's disease, bleeding disorders, and type 2 diabetes – – Shares platform advances, including potential best-in-class delivery solutions fo

− Achieved Fourth Quarter and Full Year 2024 Global Net Product Revenues of $451 Million and $1,646 Million, Respectively, Representing 30% and 33% Growth Compared to Same Periods in 2023 – − Supplemental NDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Accepted by FDA, with March 23, 2025 PDUFA Date – − Reiterates Product Sales and Profitability Guidance and Provides Additional 2025 Financial Guidance – − Company to Host and Webcast R&D Day on February 25, 2025 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the

– Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 33% Annual Growth – – 2025 Combined Net Product Revenue Guidance** of $2,050 Million to $2,250 Million Positions Company to Achieve Alnylam P5x25 Goal of Non-GAAP Profitability – – Robust Clinical Pipeline with Multi-Billion-Dollar Opportunities for Sustainable Growth – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. In addition, the Company provided 2025 net product revenue, non-GA

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. As part of the presentation, the Company will discuss unaudited fourth quarter and full year 2024 global net product revenues. A live audio webcast of both the presentation and Q&A session will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event

GIVLAARI is the first and only therapy in Canada proven to prevent AHP attacks, reduce chronic pain and improve quality of life1 MISSISSAUGA, ON, Dec. 23, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that GIVLAARI® (givosiran injection) is now funded across Canada through both public and private insurance plans for patients living with acute hepatic porphyria (AHP), including those diagnosed with acute intermittent porphyria (AIP) - the most common type of AHP. GIVLAARI is approved by Health Canada for the treatment of acute hepatic porphyria (AHP) in adults.1 It is the first and only therapy in Canada that is proven to prevent AHP attacks, reduce chronic pain and improve quality

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the

Analyst upgraded Alnylam Pharma from Neutral to Overweight and set a new price target of $328.00 from $280.00 previously

Wolfe Research downgraded Alnylam Pharma from Peer Perform to Underperform

Scotiabank initiated coverage of Alnylam Pharma with a rating of Sector Outperform

Goldman upgraded Alnylam Pharma from Neutral to Buy and set a new price target of $370.00 from $198.00 previously

Goldman downgraded Alnylam Pharma from Buy to Neutral and set a new price target of $173.00

Wolfe Research initiated coverage of Alnylam Pharma with a rating of Peer Perform

Wells Fargo initiated coverage of Alnylam Pharma with a rating of Equal Weight and set a new price target of $171.00

Wells Fargo initiated coverage of Alnylam Pharma with a rating of Equal Weight

Oppenheimer downgraded Alnylam Pharma from Outperform to Perform

Raymond James initiated coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $208.00

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

PRE 14A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

10-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th

– Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi

– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 35% Annual Growth (43% Using Constant Exchange Rate**) – – Strength of AMVUTTRA Launch Drove 37% Total TTR Annual Revenue Growth – – Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of Approximately $2.2 Billion – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products' commercial launches. Preliminary Four

– Appoints Carolyn Bertozzi, Ph.D., Nobel Laureate and Leading Voice for Chemical Biology, Emerging Technology, and Life Sciences Companies – – Michael W. Bonney Steps Down as Executive Chair and Continues on Board as Non-Independent Director – – Amy W. Schulman will Assume Role of Chair of the Board – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, today announces appointment of Carolyn Bertozzi, Ph.D. a Nobel Laureate to the Board. Dr. Bertozzi is known is known for her work in chemical biology. She is a pioneer for emerging technology and has founded ten biopharmaceutical companies and guided more than a dozen academic and professional organizations

– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase (KHK) for the treatment of Type 2 diabetes mellitus (T2DM). Pending regulatory authority and ethic committee approvals, the Company plans to begin enrollment in a Phase 1/2 study in healthy overweight to obese volunteers and obese patients with T2DM in early

− Product and Pipeline Goals Detail Execution across Four Commercial Brands, Including One Potential Label Expansion, and Ten Clinical Data Readouts From Proprietary and Partner Programs – − Pipeline Programs and Scientific Innovation Highlighted at R&D Day Exemplify Strength of RNAi Platform and Organic Product Engine – − Alnylam to Webcast its R&D Day Event Today at 8:30 a.m. ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2023 focused on continued commercial execution of four

– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 – – Study Also Demonstrated Encouraging Safety Profile in Patients with Cardiomyopathy of ATTR Amyloidosis – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Patisira

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved a label expansion for OXLUMO® (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate

– Piyush Sharma to Serve as Chief Ethics and Compliance Officer and Evan Lippman as Chief Corporate Development and Strategy Officer – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the appointment of two new members to the management team – Piyush Sharma as Chief Ethics & Compliance Officer (CECO), and Evan Lippman in the newly created role of Chief Corporate Development and Strategy Officer (CDSO). Both executives will report to Chief Executive Officer, Yvonne Greenstreet. "Attracting and retaining top talent is one of my top priorities, and I'm thrilled that Piyush and Evan are joining our team. Piyush brings valuable experience buil

− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today's Patients – – Only Therapeutic Approved in the U.S. to Address Both Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis − – Alnylam Offers Multiple Programs to Support Broad and Seamless Patient Access; Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for AMVUTTRA – – Alnylam to Host Conference Call Today at 6:00 pm ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today anno

− Achieved Fourth Quarter and Full Year 2024 Global Net Product Revenues of $451 Million and $1,646 Million, Respectively, Representing 30% and 33% Growth Compared to Same Periods in 2023 – − Supplemental NDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Accepted by FDA, with March 23, 2025 PDUFA Date – − Reiterates Product Sales and Profitability Guidance and Provides Additional 2025 Financial Guidance – − Company to Host and Webcast R&D Day on February 25, 2025 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the

− Achieved Third Quarter 2024 Global Net Product Revenues of $420 Million, Representing 34% Year-Over-Year Growth Compared to Q3 2023, Driven by Continued Momentum from TTR Business – − Submitted Regulatory Applications in U.S. and EU for AMVUTTRA® (vutrisiran) for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy – − Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues of $1,575 Million to $1,650 Million – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights. "Alnylam continued to deli

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2024 on Thursday, October 31, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2024 results as well as expectations for the future via conference call on Thursday, October 31, 2024 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Phar

− In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period and up to Month 42, Respectively – − In the Monotherapy Population, Reduced Composite Primary Endpoint by 33% and All-Cause Mortality up to Month 42 by 35% – − Strong Trends of Additive Efficacy on Top of Tafamidis Across Primary and Secondary Endpoints – − Demonstrated Statistically Significant Benefits on Multiple Measures of Disease Progression – − Encouraging Safety and Tolerability Profile, Consistent with Established Profile – − Results from HELIOS-B Si

– Company to Host Conference Call on August 30, 2024, at 1:00 p.m. (BST), 8:00 a.m. (ET) to Discuss Results – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Company will present results from the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy at the European Society of Cardiology (ESC) Congress 2024, taking place in London, UK, on August 30 - September 2, 2024. The Company recently announced positive topline results of the study which met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events

− Achieved Second Quarter 2024 Global Net Product Revenues of $410 Million, Representing 34% Year-Over-Year Growth Compared to Q2 2023, Driven by Continued Momentum from TTR Business, Which Delivered 37% Year-Over-Year Growth – − Reported Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations – − Updated 2024 Financial Guidance, Including Increased Combined Net Product Revenue Guidance from $1,400 Million - $1,500 Million to $1,575 Million - $1,650 Million – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today reported

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2024 results as well as expectations for the future via conference call on Thursday, August 1, 2024 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceu

− Achieved 28% and 33% Reduction in Composite of All-Cause Mortality and Recurrent Cardiovascular Events in the Overall and Monotherapy Populations, Respectively – − Reduced All-Cause Mortality by 36% and 35% in the Overall and Monotherapy Populations, Respectively, in a Pre-Specified Secondary Endpoint – − Demonstrated Clinically Significant Benefits on 6-Minute Walk Test, Kansas City Cardiomyopathy Questionnaire and NYHA Class – Key Measures of Disease Progression – − Observed Consistent Effects in All Key Subgroups, Including Baseline Tafamidis – − Demonstrated Encouraging Safety, Consistent with Established Profile – − Alnylam to File a U.S. Supplemental New Drug Application U

Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-5) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

Submission status for ALNYLAM PHARMS INC's drug ONPATTRO (SUPPL-12) with active ingredient PATISIRAN SODIUM has changed to 'Approval' on 01/13/2023. Application Category: NDA, Application Number: 210922, Application Classification: Efficacy

Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-3) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 10/06/2022. Application Category: NDA, Application Number: 214103, Application Classification: Efficacy

Submission status for ALNYLAM PHARMS INC's drug ONPATTRO (SUPPL-13) with active ingredient PATISIRAN SODIUM has changed to 'Approval' on 10/03/2022. Application Category: NDA, Application Number: 210922, Application Classification: Labeling

Submission status for ALNYLAM PHARMS INC's drug ONPATTRO (SUPPL-13) with active ingredient PATISIRAN SODIUM has changed to 'Approval' on 10/04/2022. Application Category: NDA, Application Number: 210922, Application Classification: Labeling

Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (ORIG-1) with active ingredient VUTRISIRAN has changed to 'Approval' on 06/13/2022. Application Category: NDA, Application Number: 215515, Application Classification: Type 1 - New Molecular Entity

Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-4) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 10/28/2021. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)